转移性去势抵抗性前列腺癌中BRCA1或BRCA2与ATM突变患者对奥拉帕利治疗的差异反应
这项在美国三个学术中心开展的多中心回顾性综述纳入23例携带致病性胚系和/或体细胞BRCA1/2或ATM突变、接受奥拉帕利治疗的转移性去势抵抗性前列腺癌男性。BRCA1/2突变者PSA50应答率为76%(13/17),ATM突变者为0%(0/6),差异有统计学意义(Fisher精确检验;p=0.002);BRCA1/2突变者中位无进展生存期12.3个月,ATM突变者2.4个月(风险比0.17,95%置信区间0.05-0.57;p=0.004)。作者结论认为ATM突变患者对PARP抑制剂治疗结局劣于BRCA1/2突变者,应探索替代疗法。
要点
- BRCA1/2突变者奥拉帕利PSA50应答率76%(13/17),ATM突变者0%(0/6),p=0.002。
- BRCA1/2突变者中位无进展生存期12.3个月,ATM突变者2.4个月,风险比0.17(95%置信区间0.05-0.57;p=0.004)。
- 作者结论认为ATM突变患者对PARP抑制剂治疗结局劣于BRCA1/2突变者,应探索替代疗法。
核心结论
- 携带ATM突变的转移性去势抵抗性前列腺癌男性接受PARP抑制剂治疗的结局劣于携带BRCA1/2突变者。
- 作者认为应为ATM突变患者探索替代疗法。
研究设计与样本
- 多中心回顾性综述,纳入在美国三个学术中心接受奥拉帕利治疗的23例连续转移性去势抵抗性前列腺癌男性,携带致病性胚系和/或体细胞BRCA1/2或ATM突变。
- 采用Fisher精确检验比较PSA50应答比例,采用Kaplan-Meier法估计临床和影像学无进展生存期及总生存期,并采用log-rank检验比较。
主要发现
- 研究纳入BRCA1突变2例、BRCA2突变15例、ATM突变6例。
- BRCA1/2突变者奥拉帕利PSA50应答率为76%(13/17),ATM突变者为0%(0/6)(Fisher精确检验;p=0.002)。
- BRCA1/2突变者中位无进展生存期为12.3个月,ATM突变者为2.4个月(风险比0.17,95%置信区间0.05-0.57;p=0.004)。
临床怎么用
- 作者认为,携带ATM突变的转移性去势抵抗性前列腺癌患者对PARP抑制剂治疗结局劣于BRCA1/2突变者,应为ATM突变患者探索替代疗法。
局限性
- 局限性包括回顾性设计和相对较小的样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Poly ADP-ribose polymerase (PARP) inhibitors, such as olaparib, are being explored as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) in men harboring mutations in homologous recombination DNA-repair genes. Whether responses to PARP inhibitors differ according to the affected gene is currently unknown. OBJECTIVE: To determine whether responses to PARP inhibitors differ between men with BRCA1/2 and those with ATM mutations. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter retrospective review of 23 consecutive men with mCRPC and pathogenic germline and/or somatic BRCA1/2 or ATM mutations treated with olaparib at three academic sites in the USA. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The proportion of patients achieving a ≥50% decline in prostate-specific antigen (PSA50 response) was compared using Fisher's exact test. Clinical and radiographic progression-free survival (PFS) and overall survival were estimated using Kaplan-Meier analyses and compared using the log-rank test. RESULTS AND LIMITATIONS: The study included two men with BRCA1 mutations, 15 with BRCA2 mutations, and six with ATM mutations. PSA50 responses to olaparib were achieved in 76% (13/17) of men with BRCA1/2 versus 0% (0/6) of men with ATM mutations (Fisher's exact test; p=0.002). Patients with BRCA1/2 mutations had median PFS of 12.3mo versus 2.4mo for those with ATM mutations (hazard ratio 0.17, 95% confidence interval 0.05-0.57; p=0.004). Limitations include the retrospective design and relatively small sample size. CONCLUSIONS: Men with mCRPC harboring ATM mutations experienced inferior outcomes to PARP inhibitor therapy compared to those harboring BRCA1/2 mutations. Alternative therapies should be explored for patients with ATM mutations. PATIENT SUMMARY: Mutations in BRCA1/2 and ATM genes are common in metastatic prostate cancer. In this study we compared outcomes for men with BRCA1/2 mutations to those for men with ATM mutations being treated with olaparib. We found that men with ATM mutations do not respond as well as men with BRCA1/2 mutations.
引用
- Marshall CH, Sokolova AO, McNatty AL, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol. 2019. PMID: 30797618. doi:10.1016/j.eururo.2019.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。